Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance - Summary - MDSpire
Advertisement
Clinical Observation: Temporary Disease Management with Icotinib Following Osimertinib Resistance in Lung Adenocarcinoma with EGFR L858R/C797S and Absence of T790M
To report a case of a patient with osimertinib resistance due to EGFR C797S mutation without T790M and the subsequent management with icotinib.
Approach:
Patient Case: A 71-year-old woman with stage IVB lung adenocarcinoma was treated with osimertinib for 29 months until progression, followed by treatment with icotinib.
Key Findings:
The patient developed EGFR L858R/C797S mutation after osimertinib treatment.
Icotinib treatment resulted in stable disease for 6 months.
Interpretation:
The therapeutic implications of C797S depend on the T790M status and allelic configuration.
Limitations:
The absence of post-progression tissue rebiopsy limited further analysis of the resistance mechanisms.
The findings are based on a single case report, which may not be generalizable.
Conclusion:
The case provides insights into treatment options for patients with specific EGFR mutation profiles post-osimertinib.
